News | June 12, 2022
Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Amarex Clinical Research guides its client to phase II of FDA trials
Tislelizumab is now approved in nine indications in China
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Subscribe To Our Newsletter & Stay Updated
